AI Terminal
HEMOGENYX PHARMACEUTICALS PLC
AGM Information • May 29, 2025
4938_agm-r_2025-05-29_de575af5-31e7-42e4-8a4b-653368033c34.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6553K
Hemogenyx Pharmaceuticals PLC
29 May 2025
29 May 2025
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
| Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2024 together with the directors' reports and auditor's report on those accounts | 769,396 | 97.31 | 21,278 | 2.69 | 790,674 | 18.20 | 12,514 |
| 2. To approve the Directors' Remuneration Report | 621,455 | 78.62 | 168,962 | 21.38 | 790,417 | 18.20 | 12,771 |
| 3. To authorise the re-appointment of Peter Redmond | 601,846 | 75.44 | 195,969 | 24.56 | 797,815 | 18.37 | 5,373 |
| 4. To re-appoint PKF Littlejohn LLP as auditors | 729,108 | 95.29 | 36,001 | 4.71 | 765,109 | 17.61 | 38,079 |
| 5. To authorise the Audit Committee to determine the level of the auditor's remuneration | 647,389 | 85.67 | 108,250 | 14.33 | 755,639 | 17.40 | 47,549 |
| 6. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act. | 639,852 | 81.03 | 149,808 | 18.97 | 789,660 | 18.18 | 13,528 |
| Special Resolutions | Votes for | % of votes cast for | Votes against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 7. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act. | 638,646 | 80.88 | 151,014 | 19.12 | 789,660 | 18.18 | 13,528 |
| 8. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting, | 763,850 | 96.72 | 25,924 | 3.28 | 789,774 | 18.18 | 13,414 |
(1) The Company's issued share capital ("ISC") on 27 May 2025, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 4,343,539 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | [email protected] |
| Peter Redmond, Director | [email protected] |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSELFDUEISESI